Cargando…

Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review

Anti-PD-1/PD-L1 immunotherapy reactivates T-cell activity to boost the antitumor effect and may trigger autoimmune toxicity in various organ systems involving eyeball and periocular structures at the same time. The rarity of ocular immune-related adverse events should not prevent us from paying atte...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jian, Xiao, Xiaoyue, Dong, Xiaorong, Wu, Gang, Wang, Xinghua, Zhang, Ruiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396260/
https://www.ncbi.nlm.nih.gov/pubmed/36016624
http://dx.doi.org/10.3389/fonc.2022.931074
_version_ 1784771890792890368
author Wang, Jian
Xiao, Xiaoyue
Dong, Xiaorong
Wu, Gang
Wang, Xinghua
Zhang, Ruiguang
author_facet Wang, Jian
Xiao, Xiaoyue
Dong, Xiaorong
Wu, Gang
Wang, Xinghua
Zhang, Ruiguang
author_sort Wang, Jian
collection PubMed
description Anti-PD-1/PD-L1 immunotherapy reactivates T-cell activity to boost the antitumor effect and may trigger autoimmune toxicity in various organ systems involving eyeball and periocular structures at the same time. The rarity of ocular immune-related adverse events should not prevent us from paying attention to this issue because of the bad consequences of visual impairment. This is the first case report of anti-PD-1 sintilimab-induced bilateral optic neuropathy in a 76-year-old man with squamous non-small cell lung cancer (NSCLC). The patient presented with sudden vision blurring without pain in both eyes after three therapeutic cycles of sintilimab plus chemotherapy. Based on the ophthalmic examination, laboratory, and radiological results, our patient was diagnosed with optic neuropathy complication secondary to anti-PD-1 sintilimab treatment. Consequently, sintilimab was held and systemic steroids were administered. The follow-up review showed that the vision recovered and the size of the primary tumor continued to decrease with the response assessment as the partial response. In conclusion, this case report suggested that patients with NSCLC undergoing anti-PD-1/PD-L1 therapy should be closely monitored for ophthalmic assessment and alert to the occurrence of sintilimab-induced optic neuropathy.
format Online
Article
Text
id pubmed-9396260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93962602022-08-24 Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review Wang, Jian Xiao, Xiaoyue Dong, Xiaorong Wu, Gang Wang, Xinghua Zhang, Ruiguang Front Oncol Oncology Anti-PD-1/PD-L1 immunotherapy reactivates T-cell activity to boost the antitumor effect and may trigger autoimmune toxicity in various organ systems involving eyeball and periocular structures at the same time. The rarity of ocular immune-related adverse events should not prevent us from paying attention to this issue because of the bad consequences of visual impairment. This is the first case report of anti-PD-1 sintilimab-induced bilateral optic neuropathy in a 76-year-old man with squamous non-small cell lung cancer (NSCLC). The patient presented with sudden vision blurring without pain in both eyes after three therapeutic cycles of sintilimab plus chemotherapy. Based on the ophthalmic examination, laboratory, and radiological results, our patient was diagnosed with optic neuropathy complication secondary to anti-PD-1 sintilimab treatment. Consequently, sintilimab was held and systemic steroids were administered. The follow-up review showed that the vision recovered and the size of the primary tumor continued to decrease with the response assessment as the partial response. In conclusion, this case report suggested that patients with NSCLC undergoing anti-PD-1/PD-L1 therapy should be closely monitored for ophthalmic assessment and alert to the occurrence of sintilimab-induced optic neuropathy. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9396260/ /pubmed/36016624 http://dx.doi.org/10.3389/fonc.2022.931074 Text en Copyright © 2022 Wang, Xiao, Dong, Wu, Wang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Jian
Xiao, Xiaoyue
Dong, Xiaorong
Wu, Gang
Wang, Xinghua
Zhang, Ruiguang
Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
title Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
title_full Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
title_fullStr Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
title_full_unstemmed Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
title_short Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
title_sort anti-pd-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396260/
https://www.ncbi.nlm.nih.gov/pubmed/36016624
http://dx.doi.org/10.3389/fonc.2022.931074
work_keys_str_mv AT wangjian antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview
AT xiaoxiaoyue antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview
AT dongxiaorong antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview
AT wugang antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview
AT wangxinghua antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview
AT zhangruiguang antipd1sintilimabinducedbilateralopticneuropathyinnonsmallcelllungcanceracasereportandliteraturereview